172 related articles for article (PubMed ID: 18479365)
1. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study.
Jang HC; Guler S; Shestakova M;
Int J Clin Pract; 2008 Jul; 62(7):1013-8. PubMed ID: 18479365
[TBL] [Abstract][Full Text] [Related]
2. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
3. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
Gumprecht J; Benroubi M; Borzi V; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Ligthelm R; Valensi P;
Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
5. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
Shah S; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shestakova M; Wenying Y; Valensi P;
Int J Clin Pract; 2009 Apr; 63(4):574-82. PubMed ID: 19210701
[TBL] [Abstract][Full Text] [Related]
8. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
Ligthelm RJ
Prim Care Diabetes; 2009 May; 3(2):97-102. PubMed ID: 19285933
[TBL] [Abstract][Full Text] [Related]
9. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
Moses AC; Raskin P; Khutoryansky N
Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
[TBL] [Abstract][Full Text] [Related]
10. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
[TBL] [Abstract][Full Text] [Related]
11. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
[TBL] [Abstract][Full Text] [Related]
12. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin < 7%: the results from the China cohort of the PRESENT study.
Gao Y; Guo XH
Chin Med J (Engl); 2010 May; 123(9):1107-111. PubMed ID: 20529546
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
Sharma SK; Joshi SR; Kumar A; Unnikrishnan AG; Hoskote SS; Moharana AK; Chakkarwar PN; Vaz JA;
J Assoc Physicians India; 2008 Nov; 56():859-63. PubMed ID: 19263683
[TBL] [Abstract][Full Text] [Related]
14. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
Kvapil M; Swatko A; Hilberg C; Shestakova M
Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
[TBL] [Abstract][Full Text] [Related]
15. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
Cucinotta D; Smirnova O; Christiansen JS; Kanc K; le Devehat C; Wojciechowska M; López de la Torre M; Liebl A
Diabetes Obes Metab; 2009 Jul; 11(7):700-8. PubMed ID: 19476479
[TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
[TBL] [Abstract][Full Text] [Related]
17. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
18. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
[TBL] [Abstract][Full Text] [Related]
19. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
20. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy.
Jang HC; Lee SR; Vaz JA
Diabetes Obes Metab; 2009 Jan; 11(1):20-6. PubMed ID: 18479469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
